 Neurotoxicity Syndromes
"Neurotoxicity Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method. This includes conditions caused by biologic, chemical, and pharmaceutical agents.
| Descriptor ID |
D020258
|
| MeSH Number(s) |
C10.720 C25.723.705
|
| Concept/Terms |
Neurotoxicity Syndromes- Neurotoxicity Syndromes
- Neurotoxicity Syndrome
- Syndrome, Neurotoxicity
- Syndromes, Neurotoxicity
- Neurotoxin Disorders
- Neurotoxin Disorder
- Neurotoxic Disorders
- Neurotoxic Disorder
- Neurotoxin Diseases
- Neurotoxin Disease
- Poisoning, Nervous System
- Nervous System Poisonings
- Poisonings, Nervous System
- Nervous System Poisoning
Encephalopathy, Toxic- Encephalopathy, Toxic
- Encephalopathies, Toxic
- Toxic Encephalopathies
- Toxic Encephalopathy
Toxic Encephalitis- Toxic Encephalitis
- Encephalitides, Toxic
- Encephalitis, Toxic
- Toxic Encephalitides
|
Below are MeSH descriptors whose meaning is more general than "Neurotoxicity Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Neurotoxicity Syndromes".
This graph shows the total number of publications written about "Neurotoxicity Syndromes" by people in this website by year, and whether "Neurotoxicity Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 3 | 1 | 4 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2022 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Neurotoxicity Syndromes" by people in Profiles.
-
Zhang X, Trendowski MR, Wilkinson E, Shahbazi M, Dinh PC, Shuey MM. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022 07; 11(14):2801-2816.
-
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022 04; 28(4):713-723.
-
Cohen AD, Parekh S, Santomasso BD, Gállego Pérez-Larraya J, van de Donk NWCJ, Arnulf B, Mateos MV, Lendvai N, Jackson CC, De Braganca KC, Schecter JM, Marquez L, Lee E, Cornax I, Zudaire E, Li C, Olyslager Y, Madduri D, Varsos H, Pacaud L, Akram M, Geng D, Jakubowiak A, Einsele H, Jagannath S. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022 02 24; 12(2):32.
-
Yuen C, Rezania K, Kelly T, Bishop MR. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study. Immunotherapy. 2021 10; 13(15):1261-1269.
-
Trendowski MR, Wheeler HE, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
-
Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Oncologist. 2019 08; 24(8):1039-e642.
-
Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017 11 21; 5(1):95.
-
Ginat DT. MRI of toxic leukoencephalopathy syndrome associated with methylenedioxymethamphetamine. Neurology. 2015 Feb 17; 84(7):757.
-
Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014 Mar 12; 106(5).
-
Robson MJ, Seminerio MJ, McCurdy CR, Coop A, Matsumoto RR. s Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacol Rep. 2013; 65(2):343-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|